ERBB2 and breast cancer: Histopathological assessment and IHC methods were used to evaluate the primary lesions in all 59 patients with breast cancer, revealing HER2 positivity in 43 of the 59 patients (72.9%) and HER2 negativity in 16 of the 59 patients (27.1%).